3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
68
Phase 2
30
Phase 1
17
Phase 1/2
7
Phase 4
2
Phase 2/3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Neoplasms
18
Prostatic Neoplasms
16
Breast Neoplasms
11
Recurrence
8
Leukemia, Myeloid, Acute
8
Neoplasm Metastasis
7
Precursor Cell Lymphoblastic Leukemia-Lymphoma
6
Colorectal Neoplasms
6
Ovarian Neoplasms
5
Myelodysplastic Syndromes
5
Multiple Myeloma
5
Melanoma
5
Leukemia
5
Head and Neck Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Lymphoma, Non-Hodgkin
4
Lung Neoplasms
4
Fatigue
4
Vomiting
3
Stomach Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Prostatic Neoplasms, Castration-Resistant
3
Pain
3
Oropharyngeal Neoplasms
3
Nausea
3
Mesothelioma
3
Lymphoma, Large B-Cell, Diffuse
3
Lymphoma
3
Liposarcoma
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Interventions
pembrolizumab
1
Docetaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Has results
×
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Clear all
NCT01905657
2021-10-06
MK-3475-010
Merck Sharp & Dohme LLC
Phase 2/3
Completed
1,034 enrolled
16 charts